Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro

G. Li,* Y. Zeng,* X. Chen,* N. Larmonier,* M. Sepassi,* M. W. Graner†, S. Andreansky,* M. A. Brewer‡ and E. Katsanis*

*Department of Pediatrics, University of Arizona, USA, †Duke University Medical Center, Durham, NC, USA, and ‡Department of Obstetrics and Gynecology and Biomedical Engineering, University of Arizona, USA

Summary

Tumour-derived chaperone-rich cell lysate (CRCL), which is made up of numerous heat shock proteins, has been used successfully to generate tumour-specific T cell responses and protective immunity against a wide range of murine tumours. In this study, we have investigated the potency of human ovarian cancer-derived CRCL to activate dendritic cells (DC) and to generate tumour-specific T cells in vitro. CRCL was generated from primary ovarian cancers and SKOV3-A2, a HER2/neu, Wilm's tumour gene 1 (WT1) and human leucocyte antigen (HLA)-A2 positive human ovarian tumour cell line. Peripheral blood mononuclear cells from both HLA-A2+ healthy donors and HLA-A2+ ovarian cancer patients were stimulated weekly with autologous DC loaded with ovarian tumour-derived CRCL. After four to six stimulations in vitro, specific cytokine secretion and cytotoxicity were measured. CRCL promoted interleukin (IL)-12 secretion and enhanced the immunostimulatory capacity of DC. T cells from healthy controls and from ovarian cancer patients secreted higher amounts of interferon-γ following in vitro restimulation with ovarian cancer-derived CRCL than with HER2/neu or WT1 peptide-pulsed DC. We were also able to generate cytotoxic T lymphocyte activity against cancer-specific antigens such as HER2/neu and WT1 from all healthy donors, but from only one of the four ovarian cancer patients with bulky disease. These preliminary results substantiate further the concept that CRCL may prove to be a potent adjuvant for women suffering from ovarian cancer and that this personalized vaccine may be a promising approach for active immunotherapy.

Keywords: cancer vaccine, chaperone-rich cell lysate (CRCL), dendritic cell (DC), heat shock protein (HSP), ovarian cancer

Introduction

Although ovarian cancer accounts for only 3% of all new cancer cases, it is the fifth leading cause of cancer-related death in women and the leading cause of mortality from gynaecological malignancies, with approximately 15 000 deaths annually [1]. Despite dosage escalation of cancer chemotherapy and increasingly radical surgery, the overall survival has not changed significantly. Thus, if successful adjuvant treatment could be developed for ovarian cancer that would prevent the extremely high rate of recurrence, the survival from ovarian cancer could be improved. Cancer vaccines have minimal toxicity, can target the patient’s immune response to tumours and may circumvent the intrinsic drug resistance that underlies present chemotherapeutic measures.

Ovarian cancer has been described as multiple diseases [2] and, in fact, more than 40 histological types contribute to the World Health Organization’s classification of epithelial tumour categories [3]. Thus, treating all ovarian cancers as if they were the same disease without tailoring treatment to each individual tumour has a high likelihood of failure. To develop effective immunotherapeutic strategies, there would be a need to identify different immunogenic tumour antigens. Tumour-derived heat shock protein (HSP, also referred as chaperone protein) vaccine is an individualized approach that circumvents the intricate hurdle of identifying immunogenic antigens of individual ovarian cancers. The observation that HSPs chaperone antigenic peptides of the cells from which they are derived makes them an attractive and novel personalized approach against cancer, which allows for vaccination of the host against a large repertoire of
individual tumour antigens [4–7]. In fact, tumour-derived HSPs (e.g. glucose regulated protein (GRP)94/gp96, HSP90, HSP70, calreticulin HSP110 and GRP170) have been shown to be effective immunogens in both animal models and in clinical trials [4–6,8–17].

Instead of utilizing individual HSP, our laboratory has focused its efforts on studying the potential benefits of tumour-derived HSP vaccines containing multiple HSPs. We have employed a free solution-isoelectric focusing method (FS-IEF) that enriches for immunogenic chaperones from clarified tumour lysates to obtain chaperone-rich cell lysates (CRCL) [11,18]. Given the limitations of preparing tumour vaccines from autologous tumour, CRCL offers an important advantage, in that with the same quantity of starting material we are able to obtain up to 10–20 times as much CRCL-derived proteins as with conventionally purified individual HSP [18,19]. This can be achieved in less time and with less labour [20]. Moreover, we have demonstrated that CRCL is a more effective adjuvant than purified HSPs [21,22], and we were able to generate tumour-specific responses in multiple murine models [20,21]. Thus, its rapid preparation, high-yield and potent anti-tumour activity makes CRCL a desirable immunogenic material for clinical use.

We have not studied previously the efficacy of CRCL in the human system. Preclinical studies, particularly using human peripheral blood mononuclear cells (PBMC), are needed to explore the feasibility of CRCL for immunotherapy in human cancers. This is necessary for advancing CRCL-based vaccines in phase I clinical trials. Therefore, the aim of this study was to investigate whether ovarian cancer-derived CRCL can be used to activate human T cells and elicit a tumour response in multiple murine models [20,21], and we were able to generate tumour-specific CTL in the CRCL is lower than 0·01 endotoxic units (EU)/mL. SKOV3-A2 was cultured in complete RPMI-1640 in the presence of G-418 selection medium (500 μg/mL G-418 (Invitrogen, Rockville, MD, USA). T2 cells (CRL-1992; American Type Culture Collection, Manassas, VA, USA) were used as an antigen-presenting cell line for 51Cr release assays. T2 cells, K562 [natural killer (NK)-sensitive chronic myelogenous leukaemia cell line], K562-A2 (HLA-A2+) cells kindly provided by Dr Lonnie P. Lybarger (University of Arizona) were cultured in complete RPMI-1640 medium.

**Generation of ovarian tumour-derived CRCL**

Human ovarian tumour tissues were collected from chemotherapy naive patients undergoing cytoreductive surgery for metastatic ovarian cancer. All patients signed an Institutional Review Board-approved consent form prior to surgery for procurement of tumour samples for research purposes. SKOV3-A2 cells were also harvested as another source of CRCL. FS-IEF enrichment of CRCL was performed as described previously [11,20]. Briefly, tumours were homogenized in lysis buffer and a 100 000 g supernatant was obtained and quantified by bicinchoninic acid (BCA) protein assay (Pierce Endogen, Rockford, IL, USA). The high-speed supernatant was subjected to FS-IEF in a Bio-Rad Rotofor cell (Hercules, CA, USA) for 5 h at 15 W constant power. Twenty fractions were harvested, and each fraction was analysed by sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot probing with specific antibodies for the chaperone proteins HSP70, HSP90, GRP94/gp96 and calreticulin. Fractions selected to be pooled for vaccines were those that contained all four of the above HSPs. Pooled fractions were then concentrated using Centricon devices (Millipore, Bedford, MA, USA). Detergents were removed by passage over an Extractigel matrix (Pierce Endogen). The fractions were reconstituted in phosphate-buffered saline (PBS), quantified and stored at −70°C until use. Endotoxin level of the CRCL is lower than 0·01 endotoxic units (EU)/μg of CRCL as examined by Limulus ameboocyte lysate assay (QCL-1000; BioWhittaker, Walkersville, MD, USA).

**Generation of DC**

Human leukopheresis was obtained from HLA-A2+ healthy donors or from ovarian patients after undergoing cytoreductive surgery and prior to receiving chemotherapy, according to the guidelines set forth by the Human Subjects Committee at the University of Arizona. All patients and healthy donors signed an Institutional Review Board-approved consent prior to leukopheresis. PBMC were purified using standard white blood cell separation by density centrifugation with Ficoll-Hypaque Plus (Amersham Pharmacia Biotech, Piscat-
away, NJ, USA). Aliquots of PBMC were cryopreserved in liquid nitrogen until use. DC were generated from PBMC by a modification of the methods described by Romani et al. [24]. In brief, PBMC were cultured in T75 flasks in 10 ml of medium (AIM-V; Gibco BRL, Carlsbad, CA, USA) and were allowed to adhere for 2 h at 37°C in 5% CO₂. To remove the non-adherent PBMC fraction, flasks were washed several times with PBS. X-Vivo 15 (BioWhittaker, Walkersville, MD, USA) supplemented with 1000 IU/ml of granulocyte–macrophage colony-stimulating factor (GM–CSF; Berlex, Wayne, NJ, USA) and 1000 IU/ml of IL-4 (Peprotech, Rocky Hill, NJ, USA) was added to adherent PBMC and the culture was continued for 5–6 days.

**Generation of SKOV3-A2-specific CTL**

HLA-A2⁺ CTL were generated by repeated stimulation of autologous T cells with CRCL or peptide-pulsed mature DC. Briefly, immature DC were incubated for 24 h with SKOV3-A2 CRCL or HER2/neu peptide at a final concentration of 25 µg/ml or 10 µg/ml at 37°C in 5% CO₂, followed by the addition of 100 ng/ml tumour necrosis factor (TNF)-α; R&D Systems, Minneapolis, MN, USA) and 10 µM prostaglandin E₂ (PGE₂; R&D) for 48 h to induce DC maturation. On day 0, non-adherent PBMC (1 × 10⁶/ml) were plated in 2 ml of Iscove’s modified Dulbecco’s medium (IMDM; Life Technologies, Rockville, MD, USA) with 25 mM HEPES, supplemented with 10% heat-inactivated human AB serum (Gemiini Bioproducts, Calabasas, CA, USA), 1000 U/ml penicillin-streptomycin, 2 mM l-glutamine and with pulsed mature DC (1 × 10⁷/ml) in 24-well plates at 37°C in 5% CO₂ (10 : 1 ratio of effector cells to stimulator DC). IL-7 (R&D Systems) was added at a concentration of 10 ng/ml. Starting on day 1, 300 IU/ml of IL-2 (R&D Systems) was added every 2–3 days. The T cells were restimulated weekly with pulsed autologous mature DC from day 7 after the first stimulation. At the end of the third or fourth stimulation, IFN-γ enzyme-linked immunospot (ELISOT) assays were performed. After four to six cycles of *in vitro* stimulation and selection, cytotoxicity assays (based on ⁵¹Cr release) were performed. The CTL cultures were separated further into CD4 and CD8 populations after sorting using a fluorescence activated cell sorter (FACScan; Becton Dickinson, Franklin Lakes, NJ, USA).

**ELISOT assays**

ELISOT assays were performed to measure the IL-12 secretion by DC and IFN-γ production by PBMC. For IL-12 detection, 1 × 10⁶ day 5 DC were cultured with 50 µg/ml lipopolysaccharide (LPS), ovarian tumour-derived lysate or CRCL in the presence of 1000 IU/ml GM–CSF and IL-4 for 48 h on Millipore MultiScreen-HA 96-well plates (Millititer; Millipore, Bedford, MA, USA). The plates were coated previously overnight with anti-IL-12 p70 capture antibody (10 µg/ml, BD PharMingen, San Diego, CA, USA). DC were then washed out with copious amounts of PBS + 0.05% Tween 20 (PBST). Biotinylated anti-IL-12 antibody (2 µg/ml, BD PharMingen) was added for 2 h. Free antibody was washed out, and the plates were incubated with horseradish peroxidase (HRP)-linked avidin (ABC Elite reagent, 1 drop each of Reagent A and Reagent B per 10 ml PBS; Vector Laboratories, Burlingame, CA, USA) for 1 h, following extensive washing with PBST, and then washing with PBS. Spots were visualized by the addition of the HRP substrate 3-amino-9-ethylcarbazole (AEC; Sigma Chemical, St Louis, MO, USA) prepared in acetate buffer (pH 5-0) with 0.015% hydrogen peroxide. Spots were counted using a dissecting microscope. Wells of interest were photographed with a microscope-mounted Cool SNAP CCD camera (RS Photometrics, Tucson, AZ, USA), and images were captured with RS Image, version 1-07 (Roper Scientific, Tucson, AZ, USA). The image of each well was optimized electronically to visualize the maximum number of spots. ELISPOT assays were also performed to measure IFN-γ secretion from stimulated PBMC. DC (2.5 × 10⁶ cells/well) were loaded with the indicated peptide or CRCL (25 µg/ml) and incubated with effector cells (5 × 10⁴ cells/well) in a total of 200 µl of X-Vivo 15 for 36 h at 37°C in 5% CO₂. A mouse anti-human IFN-γ monoclonal capture antibody (10 µg/ml/well; Pharmingen) and a biotinylated anti-human IFN-γ monoclonal capture antibody (2.5 µg/ml/well; Pharmingen) were applied to visualize spots.

**Mixed leucocyte reaction (MLR)**

In order to assay for allogeneic or autologous lymphocyte proliferation, varying numbers of day 5 DC were plated in a 96-well round-bottomed plate (Falcon, San Jose, CA, USA) and pulsed with 25 µg/ml of lysate, CRCL or 100 ng/ml TNF-α and 10 µM PGE₂, or were left untreated for 48 h. DC were plated in triplicate in X-Vivo medium containing 1000 IU/ml of GM–CSF and 1000 IU/ml of IL-4. DC were treated with 100 µg/ml mitomycin-C (Sigma Chemical Co.) for 20 min, and then washed three times with PBS. Allogeneic PBMC (2 × 10⁵ cells) were added to the DC in a total volume of 200 µl of medium. DC were serially diluted and incubated with the ratio of PBMC to DC ranging from 5 : 1 to 40 : 1. On day 3 of culture, cells were pulsed with 1 µCi/well [³H]-thymidine (MP Biomaterial, Costa Mesa, CA, USA) for 18 h and were then harvested using a 96-well Packard cell harvester and the radioactivity measured on a Packard beta counter (Packard Biosciences, Meriden, CT, USA) [21].

**Cytolytic activity of stimulated PBMC**

⁵¹Chromium release cytotoxicity assays were performed to evaluate the ability of stimulated PBMC to lyse the following
target cells: SKOV3-A2, SKOV3, K562, K562-A2 or T2 cells pulsed with 10 μg/ml of HLA-A2 restricted peptides, HER2/neu (KIFGSLAFL), WT1 (RMFPNAPYL) or hepatitis B virus (HBV) peptide (FLPSDYFPSV). Targets (5 × 10^3 cells/well) were labelled with 100 μCi of 51Cr (Amersham Pharmacia Biotech) in complete IMDM for 1 h. Percentage of specific lysis was calculated as [(experimental 51Cr release-spontaneous release)/(maximum release – spontaneous release)] × 100.

**Flow cytometry**

Fluorochromes fluorescein isothiocyanate (FITC) and phycoerythrin (PE)-conjugated monoclonal antibodies (BD PharMingen) were added to cell pellets, incubated for 30 min on ice and washed before analysed by flow cytometry (FACScan; Becton Dickinson).

**Results**

**Effect of ovarian tumour-derived CRCL on human DC maturation**

To generate CRCL-specific T cells from HLA-A2+ PBMC, autologous DC were used as antigen-presenting cells (APC). Previous data have demonstrated that murine DC incubated with tumour-derived CRCL had higher expression of CD40 and MHC class II on their cell surface, produced more IL-12 and had superior immunostimulatory capacity in MLR [21]. In this study, we have evaluated whether these findings would translate into the human system using CRCL from ovarian cancers. CRCL was derived from ovarian tumours or from the SKOV3-A2 cell line. DC were generated from either healthy volunteers or from ovarian cancer patient PBMC, as described in Materials and methods.

DC IL-12 secretion following stimulation with 50 μg/ml CRCL was evaluated and compared to LPS as the positive control. Compared with lysate and medium alone, CRCL-stimulated DC had increased IL-12 production as assessed by ELISPOT (Fig. 1a). We also examined whether DC pulsed
with ovarian cancer CRCL would be more effective stimulators in a MLR assay when compared to DC exposed to tumour lysate or to TNF-α and PGE2. Our results indicate that ovarian cancer-derived CRCL has superior activating effects on DC compared to tumour lysate (Fig. 1b). However, in terms of surface maturation markers, unlike our previous work in murine models, the expressions of HLA-DR, CD40, CD80, CD86 and CD83 were not significantly up-regulated by CRCL alone (data not shown).

**Generation of tumour-specific T cells**

Initially we tested the immunogenicity of the ovarian cancer-derived cell line, SKOV3-A2, in DC/PBMC combinations from healthy HLA-A2+ individuals. To maximize the stimulatory capacity of DC, we generated mature DC by two rounds of stimulation. First, immature DC were stimulated with CRCL for 24 h and this was followed by TNF-α and PGE2 exposure for another 48 h. PBMC were monitored for cytokine production by IFN-γ ELISPOT assays after four rounds of CRCL-pulsed DC stimulation. Additional experimental groups included DC that had been pulsed with irrelevant HBV peptide or relevant HER2/neu or WT1 peptide. SKOV3-A2 CRCL-pulsed DC elicited the greatest antigen-specific IFN-γ responses from responding PBMC derived from healthy individuals (Fig. 2a). This suggests that improved DC stimulation and/or a larger antigenic repertoire was provided by CRCL. The stimulated healthy donor PBMC demonstrated IFN-γ secretion following encounters with HER2/neu peptide in all cases, albeit less than CRCL, and WT1 peptide elicited only modest responses in two of three healthy donors. Similarly, stimulation of patient PBMC with CRCL resulted in specific responses in three of the four ovarian patients demonstrated by increased IFN-γ secretion (Fig. 2b). The IFN-γ responses from individual peptides were clearly not as strong as those from broader antigen exposure driven by SKOV3-A2 CRCL restimulation (Fig. 2b). These results suggest that T cells generated in the presence of DC/CRCL stimulation from both healthy donors and ovarian cancer patients could recognize either...
individual tumour antigen or a broader antigen repertoire encompassed in the tumour CRCL.

Cytolytic activity of tumour-specific T cells

After six weekly stimulations with CRCL-pulsed mature DC, cytotoxicity assays were performed to address whether antigen-specific CTL could lyse the SKOV3-A2 targets. Stimulated PBMC from all three healthy individuals (Fig. 3a) lysed the SKOV3-A2 targets. To determine MHC restriction of these T cell lines, we examined the cytotoxicity against cells not expressing HLA-A2 (SKOV3) and no lysis was observed. Some NK-mediated cytotoxicity was observed as indicated by lysis of the NK sensitive target K562. K562 cells transfected to express A2 had comparable lysis to A2 negative parental K562. These data demonstrated that tumour-derived CRCL is capable of generating CTL specific to the tumour of origin of CRCL. In contrast, CRCL loaded DC-stimulated PBMC from ovarian cancer patients demonstrated specific cytotoxicity in only one of the four patients studied (Fig. 3b). Although recognition of tumour antigen was observed as documented by IFN-γ secretion (Fig. 2b), lysis of target tumour cells was not detected in patients 1 and 4 (Fig. 3b). Patient 3, whose T cells demonstrated substantial lysis of SKOV3-A2 targets, also demonstrated the highest IFN-γ secretion by ELISPOT (Fig. 2b).

Cytolytic activity of CRCL-stimulated versus peptide-stimulated T cells

HLA-A2 restricted peptides have been shown to be potent CTL stimulators and antigens. We compared our CRCL stimulation with that by HER2/neu peptide. As shown in Fig. 4a, HER2/neu-stimulated T cells lysed T2 cells pulsed with HER2/neu peptide and SKOV3-A2 cells, which express and present this peptide. Importantly, CRCL-stimulated T cells lysed T2 cells pulsed with HER2/neu in addition to lysing the original SKOV3-A2 cells (Fig. 4b), correlating the results of our IFN-γ ELISPOT assays. This implies the presence of the HER2/neu antigen in the SKOV3-A2-derived CRCL preparations.

Cytotoxicity of the stimulated PBMC is mediated mainly by CD8+ T cells

Flow cytometric analysis demonstrated that CRCL-stimulated PBMC were comprised mainly of CD4+ and CD8+ T cells. In all healthy donors and patients 1, 3 and 4, CD4+ and CD8+ T cells attributed to 60–70% and 20–30%, respectively, of bulk cell culture after six weekly stimulations (Fig. 5a,b). In contrast, the CD8+ T cell population of patient 2 was dramatically lower at only 6% compared to 25% before stimulation (data not shown), suggesting that
there were defects in the CD8\(^+\) T cell growth in this patient. This lower yield of CD8\(^+\) T cells correlated with lower IFN-\(\gamma\) (Fig. 2b) production and cytotoxicity (Fig. 3b) in this patient. The percentages of CD56\(^+\) (NK cells) and CD14\(^+\) (monocytes) cells were low (1% and 1–3%, respectively) in both healthy donors and ovarian cancer patients.

To confirm that the cytotoxicity of the stimulated PBMC was mediated by CTL, we isolated CD4\(^+\) and CD8\(^+\) T cells from bulk cultures and performed \(^{51}\)Cr release assays. As demonstrated in Fig. 6, SKOV3-A2 targets were lysed primarily by CD8\(^+\) T cells. There was some K562 cell lysis induced by bulk cell culture compared to CD4\(^+\) or CD8\(^+\) T cells, suggesting that the overall cytotoxicity of bulk-stimulated PBMC was also comprised of NK cell-mediated lysis, but at much lower levels than that of CD8\(^+\) T cells. These results, together with the absence of cytotoxicity against SKOV3 (HLA-A2-negative) target cells, indicate that the cytotoxicity against the tumour, from which CRCL originated (SKOV3-A2), can be attributed mainly to MHC class I (HLA-A2)-restricted CD8\(^+\) T cells.

**Discussion**

Tumour cells are able to escape immunological destruction induced by certain tumour antigens due to the antigenic variability that arises from genetic instability. A single tumour antigen or a single epitope vaccine may lead to tumour escape variants and tolerance to therapy due to the immune pressure [25, 26]. Tumour-derived HSPs are personalized vaccines that carry multiple antigens of the original tumour [27, 28], circumventing the need to identify each tumour’s antigens. Compared to individual HSP, CRCL is a multiple HSP complex which can chaperone a wide variety of tumour-specific antigens. In this pilot human study, we have demonstrated for the first time that CRCL can maintain the advantages of individual HSPs as vaccines (i.e., no need to identify antigens, multivalency of the antigen ensemble and specificity of the class I restricted response) in a human *in vitro* system. We have focused on whether ovarian cancer-derived CRCL was able to generate HLA-A2 specific responses. Stimulation of autologous human DC with ovarian cancer-derived CRCL was able to generate specific CTL that were able to recognize and lyse ovarian tumour targets. Additionally, we were able to generate CTL against two different tumour antigens such as HER2/neu and WT1 in a class I-restricted manner. Therefore, as we have reported previously in mice, human CRCL is capable of generating a larger repertoire of tumour-specific CTL which are polyclonal in nature. Such T cells may respond to subdominant epitopes, which would be an important consideration as high-affinity T cells derived from self-antigens can be deleted in the thymus. Additionally, the chaperone proteins themselves have potent natural adjuvant- or cytokine-like activities on APC such as DC, thus enhancing the DC ability to process/present antigen and stimulate T cell responses, as demonstrated by IL-12 production and higher immunostimulatory capacity of CRCL-stimulated DC.

We have demonstrated that CRCL can be generated from patient tumour tissue. Compared to 1–2 mg of CRCL from 1 g of murine tumour, 0.5–1 mg CRCL could be generated from human ovarian tumour tissue. However, the overall yield of CRCL is still much higher than that of individual HSPs. Given the limitations of preparing tumour vaccines from autologous tumour, CRCL offers an important advantage in that with the same quantity of starting material we are able to obtain up to 10 times as much CRCL-derived proteins as with conventionally purified individual HSPs. This makes the method desirable from a clinical standpoint in terms of high yield from a potentially limited tumour source, and with a rapid turn-around time from tumour harvest to treatment of the patient. CRCL was also been isolated successfully from an ovarian cancer cell line culture SKOV3-A2. Instead of using solid tumour tissue, cell pellets of cell cultures after centrifugation were homogenized and applied to FS-IEF. The vaccine generated in this way was as efficient in activating DC as that from solid tumour,
suggesting that cells in culture may provide another feasible source of CRCL if inadequate tumour is available.

To measure the potential efficacy of a tumour vaccine, CTL responses against tumour antigens have been regarded as an important indicator of activity. CTL usually recognizes cytoplasmic antigens of target cells that are processed and presented as peptide complexes with MHC class I molecules [29]. Exogenous antigens can be cross-presented on MHC class I molecules of professional APCs to CD8+ T cells in certain circumstances, with the help of HSPs [28,30–33]. This mechanism had been utilized in our study to generate CTL in vitro following stimulation with mature DC pulsed with tumour-derived CRCL. Because immature DC are highly effective in taking up and processing antigens compared with mature DC, we pulsed immature DC with CRCL and induced DC to maturation after antigen pulsing. Indeed, CRCL alone could activate immature human DC as indicated by augmented IL-12 secretion and immunostimulatory capacity in MLR. Because cancer patients are immunosuppressed, their DC may have a functional defect which has been suggested to be one of the causes for T cell dysfunction in cancer patients [34,35].

Fig. 5. Phenotype of stimulated peripheral blood mononuclear cells (PBMC). Stimulated PBMC were generated from healthy donors (a) or ovarian cancer patients (b) by weekly stimulation with dendritic cells (DC) loaded with SKOV3-A2 chaperone-rich cell lysates (CRCL). Stimulated cells were double-stained for CD14+ (monocyte), CD56+ [natural killer (NK) cell], CD8+, and CD4+ T cells. Percentage of positive cells was analysed using flow cytometry.

Fig. 6. Cytotoxicity against target cells by bulk peripheral blood mononuclear cells (PBMC) or by separated CD8+ or CD4+ T cells derived from stimulated PBMC. Stimulated PBMC were generated as mentioned previously. Target SKOV3-A2 and K562 cells were labelled with 51Cr. The bulk PBMC or sorted CD8+ and CD4+ T cells were co-incubated (at the indicated E : T ratios) with labelled target cells (5 ¥ 10^5 cells/well) for 6–8 h. The percentage of target cell lysis was then determined. Representative data from patient 3 are shown. Data from healthy controls were similar. Error bars represent the mean ± s.e.m. of triplicate samples.
Following ovarian cancer CRCL stimulation, DC from both healthy donors and ovarian cancer patients revealed an increased cytokine secretion and T cell stimulatory capacity.

We have demonstrated that following CRCL stimulation of human DC, we were able to promote the expansion of both CD4+ and CD8+ T cells. Examining the ratio of CD4+ versus CD8+ T cells, there was preferential expansion of CD4+ T cells at the end of 6 weeks of restimulation. This is in sharp contrast to single purified HSP such as gp96, where an activated CD8+ T cell bias was observed [36]. This result suggests that there are qualitative differences in CRCL stimulation compared to single HSPs. However, the cytotoxicity was mainly attributed primarily to MHC class I-restricted CD8+ T cells and therefore the exact contribution of CD4+ T cells in CRCL-stimulated culture needs further investigation.

It is important to note that in spite of expansion of CD4+ T cells in the patient PBMC cultures, the CD8+ T cells were generally not able to kill tumour-specific targets, indicating that these patients may have ongoing immunosuppression. The causes of this immunosuppression need to be defined further.

Unlike other preclinical studies which have isolated PBMC from vaccinated patients [4–6,17,37], we have not yet acquired approval to immunize patients with CRCL. Therefore, we examined the function of CRCL-stimulated DC in stimulating anti-tumour T cell responses in an in vitro cell culture system. With the help of autologous DC loaded with ovarian cancer-derived CRCL, we stimulated PBMC, obtained by leukopheresis, in vitro from both healthy donors and ovarian carcinoma patients. These experiments are tedious, requiring extended culture of PBMC and weekly generation of new DC for pulsing and restimulation.

Specific IFN-γ secretion was observed in the stimulated PBMC from healthy donors and from three of four ovarian cancer patients. However, cytolytic function of stimulated T cells from ovarian cancer patients with untreated bulky disease was generally suppressed. Published preclinical studies using HSP vaccines have generally evaluated the IFN-γ secretion, without cytolytic assays, with the cytokine data correlating with the clinical responses to HSP vaccination [4–6,17]. It should be kept in mind that the absence of positive data in ⁵¹Cr release assays does not predict lack of in vivo responses. Moreover, the experimental in vitro conditions used to generate CTL are artificial, given that other cells and cytokines that are normally present in vivo may be absent in culture. However, the difference in the generated cytotoxicity between healthy volunteers and patients was striking and cannot be ignored, and suggests that chemonaive patients with widely metastatic ovarian cancer may be so immunosuppressed that their T cells have a defective response to CRCL. The nature of the defects in generating CTL in these ovarian cancer patients are not clear and need to be defined. The host immunosuppressive environment may play a vital role in this defect, which requires further study. We have observed diminished IL-2 output from Jurkat cells incubated with albumin purified from ovarian cancer patient ascites fluid, suggesting a possible systemic immunosuppression in these patients [38]. It is possible that patients may respond better after their tumour burden has been reduced with surgery and chemotherapy. These results indicate the importance of a pilot study to immunize patients with CRCL and to measure their immunological response. It also indicates that piloting the time of administration will be critical.

This study is the first to test the immunostimulatory effects of CRCL in the human system. The uniqueness of this system is that we were able to activate multiple antigenic determinants, including shared tumour antigens such as HER2/neu and WT1. Therefore it is conceivable that CRCL could deliver a broader repertoire of tumour-specific antigens that makes CRCL vaccination as individualized therapy desirable. Individual HSP such as HSP70 and gp96 have already been applied to phase II clinical trials [5,37]. The objective of this study was not to compare CRCL with individual HSPs in vitro, as our data from the murine in vivo models indicate that CRCL has significantly more activity than individual HSPs. Our goal in undertaking this study was to examine the efficacy of obtaining CRCL from human tumours and generating immunological responses in vitro. Our pilot data demonstrate that this approach may constitute a promising immunotherapeutic strategy to treat patients with ovarian cancer and therefore warrants further investigation.

Acknowledgements

We are grateful to Dr Douglas F. Lake and Dr Sara O. Dionne for providing access to their laboratory resources, Roger Fiedlerlein for the valuable assistance during the study and Lorry Velasco and Kathy Schmidt for their excellent nursing work. This study was supported by National Institutes of Health, grant no. R21 CA102410, by the Arizona Biomedical Research Commission, Tee up for Tots and Raise a Racquet for Kids.

References